NRx Pharmaceuticals, Inc. announced that Janet Rehnquist has been elected to the Company's Board of Directors where she will chair the compliance and the nominating committees. Ms. Rehnquist is an experienced healthcare lawyer who specializes in reimbursement and compliance matters. Previously, she served as Inspector General of the US Department of Health and Human Services and, before that as Assistant US Attorney for the Eastern District of Virginia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.93 USD | +3.90% | +42.23% | -36.30% |
May. 06 | NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data | DJ |
May. 06 | NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.30% | 29.39M | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- BRPA Stock
- News NRx Pharmaceuticals, Inc.
- Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors